SG11202109902SA - Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma - Google Patents

Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Info

Publication number
SG11202109902SA
SG11202109902SA SG11202109902SA SG11202109902SA SG 11202109902S A SG11202109902S A SG 11202109902SA SG 11202109902S A SG11202109902S A SG 11202109902SA SG 11202109902S A SG11202109902S A SG 11202109902SA
Authority
SG
Singapore
Prior art keywords
treatment
tyrosine kinase
kinase inhibitors
urothelial carcinoma
fgfr tyrosine
Prior art date
Application number
Other languages
English (en)
Inventor
Anne O'hagan
Ademi Santiago-Walker
Anjali Avadhani
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG11202109902SA publication Critical patent/SG11202109902SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
SG11202109902S 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma SG11202109902SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19166428 2019-03-29
EP19188971 2019-07-30
PCT/US2020/025166 WO2020205493A1 (en) 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Publications (1)

Publication Number Publication Date
SG11202109902SA true SG11202109902SA (en) 2021-10-28

Family

ID=70296138

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109902S SG11202109902SA (en) 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Country Status (15)

Country Link
US (1) US20220054484A1 (enrdf_load_stackoverflow)
EP (1) EP3946341A1 (enrdf_load_stackoverflow)
JP (2) JP7747521B2 (enrdf_load_stackoverflow)
KR (1) KR20210145211A (enrdf_load_stackoverflow)
CN (1) CN113645974A (enrdf_load_stackoverflow)
AU (1) AU2020253827A1 (enrdf_load_stackoverflow)
BR (1) BR112021019446A2 (enrdf_load_stackoverflow)
CA (1) CA3130460A1 (enrdf_load_stackoverflow)
IL (1) IL286729A (enrdf_load_stackoverflow)
JO (1) JOP20210266A1 (enrdf_load_stackoverflow)
MA (1) MA55522A (enrdf_load_stackoverflow)
MX (1) MX2021011926A (enrdf_load_stackoverflow)
PH (1) PH12021552342A1 (enrdf_load_stackoverflow)
SG (1) SG11202109902SA (enrdf_load_stackoverflow)
WO (1) WO2020205493A1 (enrdf_load_stackoverflow)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024241297A1 (en) * 2023-05-24 2024-11-28 Janssen Pharmaceutica Nv Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2262403C (en) 1995-07-31 2011-09-20 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US20110178097A1 (en) 2005-05-23 2011-07-21 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
CN107002141B (zh) 2014-09-26 2021-11-02 詹森药业有限公司 使用fgfr突变基因组鉴定将对用fgfr抑制剂进行治疗有反应的癌症患者
WO2017070708A1 (en) * 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
KR20200026787A (ko) 2017-02-06 2020-03-11 레이니어 테라퓨틱스, 인크. 암 치료를 위한 방법, 조성물, 및 키트
WO2018141921A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment
JOP20190190A1 (ar) 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Also Published As

Publication number Publication date
IL286729A (en) 2021-10-31
CA3130460A1 (en) 2020-10-08
JP2025156297A (ja) 2025-10-14
MA55522A (fr) 2022-02-09
MX2021011926A (es) 2021-11-03
JP2022527189A (ja) 2022-05-31
BR112021019446A2 (pt) 2021-11-30
CN113645974A (zh) 2021-11-12
KR20210145211A (ko) 2021-12-01
PH12021552342A1 (en) 2022-08-22
AU2020253827A1 (en) 2021-09-30
WO2020205493A1 (en) 2020-10-08
EP3946341A1 (en) 2022-02-09
US20220054484A1 (en) 2022-02-24
JOP20210266A1 (ar) 2023-01-30
JP7747521B2 (ja) 2025-10-01

Similar Documents

Publication Publication Date Title
IL286727A (en) fgfr tyrosine kinase inhibitors for the treatment of urinary tract carcinoma
IL291000A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for cancer therapy
IL279258B (en) tyrosine kinase inhibitors
EP3399968B8 (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
EP3648753A4 (en) SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF EGFR TYROSINE KINASE
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
IL283599A (en) Tyrosine kinase inhibitors, preparations and methods
EP3448852A4 (en) NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF TYROSINE KINASE BCR-ABL
DK3972604T3 (da) Brutons tyrosinkinasehæmmer til anvendelse ved behandling af kronisk spontan urticaria
EP3328496A4 (en) Inhibitors of ack1/tnk2 tyrosine kinase
MX393992B (es) Compuestos de aminotiazol como inhibidores de la proteina quinasa
IL284857A (en) Methods for treating diarrhea caused by a TYROSINE KINASE inhibitor
EP4169918B8 (en) Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer
EP3999064A4 (en) Inhibitors of tyrosine kinase
IL290798A (en) Tyrosine kinase inhibitor drugs for cancer treatment
SG11202109902SA (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
SG10201909596RA (en) Synthesis of Tyrosine Kinase Inhibitors
HK40068921A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40068919A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
EP3923947A4 (en) FGFR INHIBITORS FOR THE TREATMENT OF CANCER
EP3774818A4 (en) TYROSINE KINASE INHIBITORS FMS TYPE
GB201807845D0 (en) Kinase Inhibitors
HK40109644A (en) Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
HK40075155A (en) Inhibitors of tyrosine kinase